Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment

被引:197
作者
Crettol, S
Déglon, JJ
Besson, J
Croquette-Krokkar, M
Gothuey, I
Hämmig, R
Monnat, M
Hüttemann, H
Baumann, P
Eap, CB [1 ]
机构
[1] Univ Lausanne, Hop Cery, Ctr Neurosci Psychiat, Dept Psychiat Adulte,Unite Biochim & Psychopharma, CH-1008 Lausanne, Switzerland
[2] Fdn Phenix, Geneva, Switzerland
[3] CHU Vaudois, Ctr St Martin, Unite Toxicodependance, Dept Psychiat, CH-1011 Lausanne, Switzerland
[4] Hop Cantonal Univ Geneva, Dept Psychiat, Montreux, Switzerland
[5] Unite Ambulatoire Specialisee, Montreux, Switzerland
[6] Univ Bern, Psychiat Dienste Bern, Bern, Switzerland
关键词
D O I
10.1016/j.clpt.2005.08.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objective: Recent in vitro studies have suggested an important role of cytochrome P450 (CYP) 2B6 and CYP2C19 in methadone metabolism. We aimed to determine the influence of CYP2B6, CYP2C9, and CYP2C19 genetic polymorphism on methadone pharmacokinetics and on the response to treatment. Methods. We included 209 patients in methadone maintenance treatment on the basis of their response to treatment and their daily methadone dose. Patients were genotyped for CYP2B6, CYP2C9, and CYP2C19. Steady-state trough and peak (R)-, (S)-, and (RS)-plasma levels and peak-to-trough plasma level ratios were measured. Results: CYP2B6 genotype influences (S)-methadone and, to a lesser extent, (R)-methadone plasma levels, with the median trough (S)-methadone plasma levels being 105, 122, and 209 ng (.) kg/mL (.) mg for the noncarriers of allele *6, heterozygous carriers, and homozygous carriers (*6/*6), respectively (P = .0004). CYP2C9 and CYP2C19 genotypes do not influence methadone plasma levels. Lower peak and trough plasma levels of methadone and higher peak-to-trough ratios were measured in patients considered as nonresponders [median (R,S)-methadone trough plasma levels of 183 and 249 ng (.) kg/mL (.) mg (P = .0004) and median peak-to-trough ratios of 1.82 and 1.58 for high-dose nonresponders and high-dose responders, respectively (P = .0003)]. Conclusion: Although CYP2B6 influences (S)-methadone plasma levels, given that only (R)-methadone contributes to the opioid effect of this drug, a major influence of CYP2B6 genotype on response to treatment is unlikely and has not been shown in this study. Lower plasma levels of methadone in nonresponders, suggesting a higher clearance, and higher peak-to-trough ratios, suggesting a shorter elimination half-life, are in agreement with the usual clinical measures taken for such patients, which are to increase methadone dosages and to split the daily dose into several intakes.
引用
收藏
页码:593 / 604
页数:12
相关论文
共 46 条
[41]  
*URL, HUM CYT P450 CVP ALL
[42]   Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro [J].
Wang, JS ;
DeVane, CL .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (06) :742-747
[43]   The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity [J].
Ward, BA ;
Gorski, JC ;
Jones, DR ;
Hall, SD ;
Flockhart, DA ;
Desta, Z .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 306 (01) :287-300
[44]   Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world [J].
Xie, HG ;
Stein, CM ;
Kim, RB ;
Wilkinson, GR ;
Flockhart, DA ;
Wood, AJJ .
PHARMACOGENETICS, 1999, 9 (05) :539-549
[45]   Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation [J].
Xie, HJ ;
Yasar, Ü ;
Lundgren, S ;
Griskevicius, L ;
Terelius, Y ;
Hassan, M ;
Rane, A .
PHARMACOGENOMICS JOURNAL, 2003, 3 (01) :53-61
[46]   Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes [J].
Yamazaki, H ;
Inoue, K ;
Hashimoto, M ;
Shimada, T .
ARCHIVES OF TOXICOLOGY, 1999, 73 (02) :65-70